6 years ago

Quell Therapeutics Launches with £35 Million Series A to Develop Treg Cell Therapies

  • Syncona has founded Quell Therapeutics, a cell therapy company, with a £35 million Series A financing

  • Quell Therapeutics will develop engineered T regulatory cell therapies for conditions like organ transplant rejection and autoimmune diseases

  • Syncona led the round with a £34 million investment, and UCL Technology Fund contributed £1 million.

      • ProblemHealthcare

      "Solid organ transplant rejection, autoimmune and inflammatory diseases are serious conditions that lack effective treatments."

      Solution

      "Quell Therapeutics is developing engineered T regulatory cell therapies that harness the immune-suppressive capacity of Treg cells to treat these conditions."

      Covered on